NVONYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NONOF
NOVO NORDISK A S
Financials through fiscal 2025, year ended Dec 31, 2025
$38.42−0.41 (-1.06%)
Close on Oct 19, 2026
Share price
−$15.95 (−29.34%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Ex-dividend
NOVO NORDISK A S grew revenue 6.4% to 309.06B DKK over fiscal 2025. Operating income fell 0.5% to 127.66B DKK, moving the operating margin from 44.2% to 41.3%. Free cash flow was 58.96B DKK, down 20.1% from a year earlier.
Revenue
309.06B DKK
+6.4% vs. a year earlier
Operating income
127.66B DKK
-0.5% vs. a year earlier
Free cash flow
58.96B DKK
-20.1% vs. a year earlier
EPS, diluted
23.03 DKK
+1.8% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- 309.06B DKK
- EPS, diluted
- 23.03 DKK
- Free cash flow
- 58.96B DKK
Valuation needs the share price. It fills in once daily prices are connected and converted from DKK.
Twelve years at a glance
Fiscal years 2014 to 2025, DKK
Revenue
309.06B DKK+6.4% YoY
Gross profit
250.28B DKK+1.8% YoY
Operating income
127.66B DKK-0.5% YoY
EPS, diluted
23.03 DKK+1.8% YoY
Free cash flow
58.96B DKK-20.1% YoY
Reported period